Bio Green Med Solution, Inc. (BGMS) Cash Flow Statement
Where BGMS’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- −$4.8M
- Capital expenditures
- $0 0.0% of revenue
- Free cash flow
- −$4.8M −638.6% margin
- Returned to shareholders
- $61,000
- Change in cash
- $368,000 cash at year-end $3.5M
Drawn to scale: where the cash came from and how it was used. Hover for values.
BGMS operating cash flow, capex and free cash flow
BGMS cash flow trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$10.1M2016 | −$4.8M2025 | — | |
| Capital expenditures | $3,0002016 | $02025 | −100.0% | |
| Free cash flow | −$10.1M2016 | −$4.8M2025 | — | |
| Free cash flow margin | −1,196.0%2016 | −638.6%2025 | +557.4 pts | |
| Stock-based compensation | $782,0002016 | $2.3M2025 | +12.9%/yr | |
| Dividends paid | $200,0002016 | $61,0002025 | −12.4%/yr | |
| Capex / revenue | 0.4%2016 | 0.0%2025 | −0.4 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
BGMS cash flow by activity
BGMS net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
BGMS cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$3.0M | −$11.2M | −$22.6M | −$21.2M | −$18.5M | −$8.4M | −$7.8M | −$7.3M | −$7.5M | −$11.8M |
| Depreciation & amortization | $5,000 | $6,000 | $31,000 | $32,000 | $43,000 | $20,000 | $20,000 | $29,000 | $32,000 | $133,000 |
| Stock-based compensation | $2.3M | $592,000 | $1.5M | $1.5M | $1.2M | $430,000 | $466,000 | $331,000 | $266,000 | $782,000 |
| Change in working capital | −$9.1M | $2.6M | $4.9M | −$1.2M | −$1.3M | $124,000 | $214,000 | −$327,000 | $1.2M | $439,000 |
| Other non-cash items | $4.9M | $0 | $0 | $0 | $0 | −$63,000 | −$2.3M | $554,000 | −$1.5M | $358,000 |
| Cash from operating activities | −$4.8M | −$8.0M | −$16.1M | −$20.8M | −$18.5M | −$7.9M | −$9.4M | −$6.7M | −$7.5M | −$10.1M |
| Investing activities | ||||||||||
| Capital expenditures | $0 | $0 | −$6,000 | −$7,000 | −$27,000 | −$96,000 | −$10,000 | −$39,000 | −$13,000 | −$3,000 |
| Investments (net) | — | $0 | −$6,000 | −$7,000 | −$27,000 | — | — | — | — | — |
| Acquisitions & other investing | — | — | $6,000 | $7,000 | $27,000 | $0 | $38,000 | $0 | $0 | $12,000 |
| Cash from investing activities | — | — | −$6,000 | −$7,000 | −$27,000 | −$96,000 | $28,000 | −$39,000 | −$13,000 | $9,000 |
| Financing activities | ||||||||||
| Dividends paid | −$61,000 | $0 | −$201,000 | −$201,000 | −$201,000 | −$201,000 | −$201,000 | −$201,000 | −$201,000 | −$200,000 |
| Shares issued | $6.4M | $6.2M | $1.0M | $3.2M | $17.4M | $0 | $0 | $0 | $0 | $0 |
| Other financing | −$1.1M | $1.6M | $0 | $0 | $4.6M | $29.7M | $4.0M | $630,000 | $14.9M | $6.8M |
| Cash from financing activities | $5.3M | $7.8M | $848,000 | $3.0M | $21.7M | $29.5M | $3.8M | $429,000 | $14.7M | $6.6M |
| Summary | ||||||||||
| Net change in cash | $368,000 | −$241,000 | −$15.0M | −$18.2M | $3.2M | $21.5M | −$5.6M | −$6.4M | $7.4M | −$3.9M |
| Cash at end of period | $3.5M | $3.1M | $3.4M | $18.3M | $36.6M | $33.4M | $11.9M | $17.5M | $23.9M | $16.5M |
| Free cash flow | −$4.8M | −$8.0M | −$16.1M | −$20.8M | −$18.6M | −$8.0M | −$9.5M | −$6.7M | −$7.5M | −$10.1M |
| Free cash flow margin | −638.6% | −18,581.4% | −3,837.6% | — | — | — | — | −4,493.3% | — | −1,196.0% |
| Capex / revenue | 0.0% | 0.0% | 1.4% | — | — | — | — | 26.0% | — | 0.4% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$405,000 | −$197,000 | −$611,000 | −$988,000 | −$1.3M | −$81,000 | −$3.1M | −$2.0M | −$3.3M | −$2.9M | −$5.3M | −$6.0M |
| Depreciation & amortization | $0 | $1,000 | $4,000 | $0 | $1,000 | $0 | $1,000 | $1,000 | $2,000 | $2,000 | $8,000 | $7,000 |
| Stock-based compensation | $0 | $1,000 | $655,000 | $6,000 | $7,000 | $1.7M | $93,000 | $107,000 | $189,000 | $203,000 | $322,000 | $390,000 |
| Change in working capital | $53,000 | −$81,000 | −$83,000 | −$1.8M | −$4.7M | −$4.8M | $1.6M | −$1.2M | −$2,000 | $2.0M | $1.3M | $75,000 |
| Other non-cash items | $0 | −$2,000 | $2,000 | $2.3M | $4.9M | $9,000 | $37,000 | −$5,000 | −$16,000 | $238,000 | −$317,000 | $1.5M |
| Cash from operating activities | −$352,000 | −$278,000 | −$33,000 | −$434,000 | −$1.1M | −$3.2M | −$1.4M | −$3.1M | −$3.1M | −$483,000 | −$3.9M | −$4.0M |
| Investing activities | ||||||||||||
| Capital expenditures | $0 | −$1,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Investments (net) | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 | — | — | — |
| Acquisitions & other investing | — | $0 | — | — | — | — | — | — | — | — | — | — |
| Cash from investing activities | — | −$1,000 | — | — | — | — | — | — | — | — | — | — |
| Financing activities | ||||||||||||
| Dividends paid | −$21,000 | −$20,000 | −$20,000 | $0 | −$41,000 | $0 | $0 | $0 | $0 | — | −$50,000 | −$50,000 |
| Shares issued | $794,000 | $125,000 | $861,000 | $0 | $1.7M | $3.9M | $0 | $0 | $6.2M | $0 | $0 | $0 |
| Other financing | $0 | $0 | −$1.1M | −$3,000 | $248,000 | −$248,000 | $1.6M | −$1,000 | $79,000 | −$79,000 | $1.0M | $0 |
| Cash from financing activities | $773,000 | $105,000 | −$259,000 | −$3,000 | $1.9M | $3.6M | $1.6M | −$1,000 | $6.3M | −$79,000 | $999,000 | −$50,000 |
| Summary | ||||||||||||
| Net change in cash | $451,000 | −$166,000 | −$333,000 | −$437,000 | $825,000 | $313,000 | $155,000 | −$3.0M | $3.2M | −$580,000 | −$2.6M | −$4.2M |
| Cash at end of period | $3.8M | $3.3M | $3.5M | $3.8M | $4.3M | $3.5M | $3.1M | $3.0M | $6.0M | $2.8M | $3.4M | $5.9M |
| Free cash flow | −$352,000 | −$279,000 | −$33,000 | −$434,000 | −$1.1M | −$3.2M | −$1.4M | −$3.1M | −$3.1M | −$483,000 | −$3.9M | −$4.0M |
| Free cash flow margin | −104.8% | −35.9% | −5.0% | −535.8% | — | — | — | −30,670.0% | −77,100.0% | −1,665.5% | −12,612.9% | −25,225.0% |
| Capex / revenue | 0.0% | 0.1% | 0.0% | 0.0% | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
BGMS cash generation
In fiscal 2025 (ended December 31, 2025), Bio Green Med Solution generated -$4.8 million of cash from operations and spent $0 on capital expenditures, leaving free cash flow of -$4.8 million, −638.6% of revenue. It returned $0.1 million to shareholders through dividends ($0.1 million) and net share buybacks ($0). Cash and equivalents rose by $0.4 million over the year.
Related: BGMS income statement, BGMS balance sheet. See the BGMS stock overview for the latest quote and news.
BGMS cash flow FAQ
What is Bio Green Med Solution's free cash flow?
Bio Green Med Solution's free cash flow was -$4.8 million in fiscal 2025: -$4.8 million of operating cash flow minus $0 of capital expenditures It was -$8.0 million a year earlier..
How much cash does Bio Green Med Solution generate from operations?
Bio Green Med Solution generated -$4.8 million of cash from operating activities in fiscal 2025.
How much does Bio Green Med Solution pay in dividends?
Bio Green Med Solution paid $0.1 million in dividends in fiscal 2025.